

# CITATION REPORT

List of articles citing

**Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability**

**DOI: 10.1016/s0002-8703(96)90525-6**  
**American Heart Journal, 1996, 131, 472-80.**

**Source:** <https://exaly.com/paper-pdf/26749956/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
135	Non-sedating antihistamines and cardiac arrhythmia. <b>1997</b> , 350, 1115-6		20
134	Influence of age on Henoch Schölein purpura. <b>1997</b> , 350, 1116-7		23
133	Changes in repolarization dynamicity and the assessment of the arrhythmic risk. <b>1997</b> , 20, 2614-24		44
132	Electrocardiographic findings in patients with diphenhydramine overdose. <b>1997</b> , 80, 1168-73		88
131	The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. <b>1998</b> , 64, 542-6		127
130	Cardiac adverse effects of H1-antihistamines. <b>1998</b> , 38, 931-934		
129	High Resolution Electrocardiography's Application for the Measurement of the QT Interval in the Presence of Low Amplitude T Waves. <b>1998</b> , 3, 304-310		1
128	Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. <b>1998</b> , 101, 410-20		113
127	Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist. <b>1999</b> , 47, 515-20		17
126	The current cardiac safety situation with antihistamines. <b>1999</b> , 29, 15-24		25
125	QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine. <b>1999</b> , 29 Suppl 3, 206-11		15
124	Cardiovascular safety of fexofenadine HCl. <b>1999</b> , 29 Suppl 3, 212-6		38
123	How to Obtain and Analyze Electrocardiograms in Clinical Trials. <b>1999</b> , 4, 425-433		19
122	Electrocardiographic abnormalities during recovery from ultra-short opiate detoxification. <b>1999</b> , 4, 337-44		9
121	Cardiovascular safety of fexofenadine HCl. <b>1999</b> , 83, 1451-4		87
120	Cardiac complications in the intensive care unit. <b>1999</b> , 20, 269-85		5
119	Comparative tolerability of second generation antihistamines. <i>Drug Safety</i> , <b>1999</b> , 20, 385-401	5.1	39

118	Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. <b>1999</b> , 103, 1025-30		38
117	The effect of pharmacokinetically guided acute intravenous testosterone administration on electrocardiographic and blood pressure variables. <b>1999</b> , 39, 1038-43		19
116	Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective. <b>1999</b> , 39, 349-58		27
115	Drug-induced proarrhythmic effects: assessment of changes in QT interval. <b>2000</b> , 50, 297-302		26
114	QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. <i>European Journal of Clinical Pharmacology</i> , <b>2000</b> , 56, 1-18	2.8	222
113	Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. <b>2000</b> , 1, 947-73		120
112	The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. <b>2000</b> , 21, 1216-31		286
111	Les effets secondaires cardiovasculaires des anti-H1. <b>2000</b> , 40, 349-354		1
110	Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. <b>2000</b> , 38, 41-57		623
109	The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. <i>Journal of Cardiovascular Pharmacology</i> , <b>2001</b> , 37, 607-18	3.1	145
108	Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. <i>European Journal of Clinical Pharmacology</i> , <b>2001</b> , 57, 185-209	2.8	158
107	Effects of suprathreshold doses of ebastine and terfenadine on the QT interval. <b>2001</b> , 52, 201-4		29
106	Lack of effect of reboxetine on cardiac repolarization. <b>2001</b> , 70, 261-9		26
105	Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. <b>2001</b> , 21, 301-19		80
104	Focus on issues in measuring and interpreting changes in the QTc interval duration. <b>2001</b> , 3, K105-K111		25
103	Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomes. <b>2002</b> , 11, 197-202		0
102	The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. <b>2002</b> , 302, 828-33		47
101	[Adverse drug reactions. QT-prolongation and torsade-de-pointes arrhythmias]. <b>2002</b> , 127, 1022-4		3

100	Development of drugs that alter ventricular repolarization. <b>2002</b> , 9, 127-39	4
99	QT interval prolongation as a biomarker for torsades de pointes and sudden death in drug development. <b>2002</b> , 18, 57-62	27
98	Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. <b>2002</b> , 16, 147-56	68
97	The significance of QT interval in drug development. <b>2002</b> , 54, 188-202	170
96	Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. <b>2003</b> , 33, 1305-24	129
95	Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization. <b>2003</b> , 43, 974-82	2
94	Cardiovascular safety of salmeterol in COPD. <b>2003</b> , 123, 1817-24	81
93	Risk of QT Prolongation and Torsades de Pointes with Antihistamines. 87-101	
92	. <b>2004</b> ,	16
91	Measurement of the QT Interval and Repolarization Assessment. 24-59	3
90	Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. <b>2004</b> , 9 Suppl 1, S65-83	104
89	Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. <b>2004</b> , 9, 48-57	73
88	Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. <b>2004</b> , 9, 166-74	33
87	A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. <b>2004</b> , 37, 25-9	42
86	Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. <b>2004</b> , 486, 209-21	60
85	Safety of droperidol in behavioural emergencies. <b>2004</b> , 3, 369-78	11
84	Drug-induced prolongation of the QT interval. <b>2004</b> , 350, 1013-22	1513
83	Individual QT-R-R relationship: average stability over time does not rule out an individual residual variability: implication for the assessment of drug effect on the QT interval. <b>2005</b> , 10, 169-78	14

82	Drug-induced QT dispersion: does it predict the risk of torsade de pointes?. <b>2005</b> , 38, 10-8	58
81	Accuracy of popular automatic QT interval algorithms assessed by a 'gold standard' and comparison with a Novel method: computer simulation study. <b>2005</b> , 5, 29	10
80	Effects of methadone on QT-interval dispersion. <b>2005</b> , 25, 1523-9	56
79	Dose Ranging Crossover Designs. <b>2005</b> , 1-17	
78	Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. <b>2005</b> , 39, 243-265	40
77	ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. <b>2005</b> , 39, 387-394	8
76	The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. <b>2005</b> , 46, 678-87	27
75	Clinical outcomes and adverse effect monitoring in allergic rhinitis. <b>2005</b> , 115, S390-413	109
74	Cardiac Safety of Noncardiac Drugs. <b>2005</b> ,	8
73	Drug-induced q-T prolongation. <b>2005</b> , 89, 1125-44, x	35
72	Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. <b>2006</b> , 46, 498-507	137
71	Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. <b>2006</b> , 3, 1003-7	123
70	Magnitude of error introduced by application of heart rate correction formulas to the canine QT interval. <b>2006</b> , 11, 289-98	11
69	Implications of methodological differences in digital electrocardiogram interval measurement. <b>2006</b> , 39, S152-6	29
68	Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG Warehouse. <b>2007</b> , 6, 595-607	5
67	On the relationship among QT interval, atrial fibrillation, and torsade de pointes. <b>2007</b> , 9 Suppl 4, iv1-3	10
66	Droperidol-induced proarrhythmia: the beginning of an answer?. <b>2007</b> , 107, 524-6	8
65	Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance. <i>Drug Safety</i> , <b>2007</b> , 30, 1093-110	5.1 30

64	Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs. <b>2007</b> , 171-84	8
63	Cardiac repolarization and the safety of new drugs defined by electrocardiography. <b>2007</b> , 81, 108-13	48
62	Autonomic tone attenuates drug-induced QT prolongation. <b>2007</b> , 18, 960-4	13
61	Mouse models of human arrhythmia syndromes. <b>2008</b> , 192, 455-69	29
60	The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. <b>2008</b> , 84, 475-80	125
59	Moving towards better predictors of drug-induced torsades de pointes. <b>2008</b> , 154, 1550-3	15
58	The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. <b>2008</b> , 154, 1457-64	23
57	Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. <b>2008</b> , 5, 1213-5	32
56	Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. <b>2008</b> , 48, 13-8	191
55	Pharmacokinetic and Pharmacodynamic Characterization of Non-antiarrhythmic QT-Prolonging Drugs Associated with Torsades de Pointes. <b>2008</b> , 42, 211-219	4
54	A hybrid wavelet and time plane based method for QT interval measurement in ECG signals. <b>2008</b> ,	1
53	Dose Ranging Crossover Designs. <b>2008</b> , 1	
52	Drug-Induced QT Interval Prolongation Regulatory Guidance and Perspectives on hERG Channel Studies. <b>2008</b> , 251-285	32
51	[Medication associated long QT syndrome]. <b>2009</b> , 98, 1409-15; quiz 1415	10
50	Antipsychotic-induced sudden cardiac death: examination of an atypical reaction. <b>2009</b> , 8, 249-52	6
49	The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2009</b> , 60, 11-23	1.7 22
48	Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry. <b>2009</b> , 14, 589-97	17
47	Sevoflurane and QTc Prolongation: An Interesting Observation, or a Clinically Significant Finding?. <b>2010</b> , 113, 772-5	10

46	Drug-induced long QT syndrome. <b>2010</b> , 62, 760-81		296
45	Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential. <b>2010</b> , 159, 77-92		36
44	Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. <b>2010</b> , 159, 34-48		75
43	Preferred QT correction formula for the assessment of drug-induced QT interval prolongation. <b>2010</b> , 21, 905-13		32
42	Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval). <b>2010</b> , 87, 166-74		34
41	Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. <b>2010</b> , 55, 2745-52		143
40	Thorough QT Studies: Questions and Quandaries. <i>Drug Safety</i> , <b>2010</b> , 33, 1-14	5.1	45
39	QTc prolongation as a surrogate for drug-induced arrhythmias: fact or fallacy?. <b>2011</b> , 66, 685-9		13
38	Drug-induced QTc prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. <i>Journal of Cardiovascular Pharmacology</i> , <b>2011</b> , 57, 589-97	3.1	31
37	Reference regions for beat-to-beat ECG data. <b>2011</b> , 10, 162-8		1
36	Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?. <b>2012</b> , 166, 1490-502		35
35	Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, 339-51	3.2	30
34	Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?. <i>Drug Safety</i> , <b>2013</b> , 36, 167-82	5.1	110
33	QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes. <i>Journal of Anesthesia</i> , <b>2013</b> , 27, 575-87	2.2	14
32	Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 1222-32	2.6	17
31	Dose Ranging Crossover Designs. <b>2013</b> , 1		
30	Dose Ranging Crossover Designs. <b>2014</b> ,		
29	Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 146-55	1.9	5

28	Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 6-13	3.5	20
27	Dose Ranging Crossover Designs. <b>2014</b> , 362-382		
26	Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1001-9	2.8	10
25	[Long QT syndrome. History, genetics, clinical symptoms, causes and therapy]. <i>Der Anaesthetist</i> , <b>2015</b> , 64, 586-95	2.2	2
24	Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model. <i>Journal of Cardiovascular Pharmacology</i> , <b>2016</b> , 67, 237-45	3.1	18
23	Predicting drug-induced QT prolongation and torsades de pointes. <i>Journal of Physiology</i> , <b>2016</b> , 594, 2453-68	3.68	98
22	Murine Electrophysiological Models of Cardiac Arrhythmogenesis. <i>Physiological Reviews</i> , <b>2017</b> , 97, 283-409	4.9	66
21	Risk Management of Hospitalized Psychiatric Patients Taking Multiple QTc-Prolonging Drugs. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 540-545	1.7	11
20	Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 465-470	3.1	7
19	QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2018</b> ,	2.1	15
18	On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships. <i>Scientific Reports</i> , <b>2019</b> , 9, 9619	4.9	46
17	A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 895-903	9.9	19
16	Arrhythmogenic foods - A growing medical problem. <i>Trends in Cardiovascular Medicine</i> , <b>2020</b> , 30, 310-317	6.9	7
15	Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2020</b> , 101, 106654	1.7	7
14	Editorial commentary: A question on proarrhythmic food: Is grapefruit "the forbidden fruit" for patients with long QT syndrome?. <i>Trends in Cardiovascular Medicine</i> , <b>2020</b> , 30, 313-314	6.9	2
13	In Vivo and In Vitro Protective Effects of Rosmarinic Acid against Doxorubicin-Induced Cardiotoxicity. <i>Nutrition and Cancer</i> , <b>2021</b> , 1-15	2.8	3
12	Update: Clinically Significant Cytochrome P-450 Drug Interactions. <b>1998</b> , 18, 84-112		124
11	QT Interval and Its Drug-Induced Prolongation. <i>Contemporary Cardiology</i> , <b>2003</b> , 311-328	0.1	1



10	Design and Conduct of the Thorough Phase I ECG Trial for New Bioactive Drugs. <b>2005</b> , 205-222	3
9	Interpretation of Clinical ECG Data. <b>2005</b> , 259-298	3
8	Acquired (Drug-Induced) Long QT Syndrome. <b>2008</b> , 705-718	3
7	References. <b>2000</b> ,	
6	Designing and interpreting the results of first-time-to-man studies. <i>Dialogues in Clinical Neuroscience</i> , <b>2000</b> , 2, 203-12	5-7 2
5	Points to Consider to Design the Thorough QT/QTc Study <i>Japanese Journal of Biometrics</i> , <b>2008</b> , 29, S75-S82	0
4	Polypharmazie [Medikamente und QTc-Zeit. Was ist zu beachten?]. <i>Kardiologie Up2date</i> , <b>2020</b> , 16, 331-340	
3	Cellular, Molecular, and Pharmacologic Mechanisms Underlying Drug-Induced Cardiac Arrhythmogenesis. <b>2005</b> , 37-66	
2	Digital 12-Lead Holter vs Standard Resting Supine Electrocardiogram for the Assessment of Drug-Induced QTc Prolongation. <b>2005</b> , 147-166	
1	Emerging risk factors for QT interval prolongation and torsades de pointes. <b>2022</b> , 113-156	0